GlobeNewswire by notified

Sampo has received approvals for the dual listing on Nasdaq Stockholm

Share

SAMPO PLC            STOCK EXCHANGE RELEASE          15 November 2022 at 9:30 am EST

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS.

Sampo has received approvals for the dual listing on NasdaqStockholm

Sampo plc has received approval from Nasdaq Stockholm to proceed with a dual listing on Nasdaq Stockholm. Trading is expected to commence on 22 November 2022 and Sampo has today published a listing prospectus, approved and registered by the Swedish Financial Supervisory Authority, at the company’s website at www.sampo.com/duallisting.

The dual listing and trading on Nasdaq Stockholm will be carried out in Swedish Depositary Receipts (SDRs), and for that purpose, Sampo has appointed Skandinaviska Enskilda Banken AB (SEB) as issuer of the SDRs and custody bank for the SDR arrangement. The dual listing does not require any action from Sampo’s current shareholders, unless they would like to convert their Nasdaq Helsinki listed Sampo A shares to SDRs. Pursuant to Finnish law, Finnish legal and natural persons are not entitled to own SDRs.

Holders of Sampo A shares will be able to convert their Sampo A shares to SDRs, and holders of SDRs will be able to convert their SDRs into Sampo A shares, in accordance with the General Terms and Conditions for the Swedish Depository Receipts in Sampo (SDR General Terms and Conditions). The SDRs are governed by the SDR General Terms and Conditions which are summarized in the listing prospectus and are available in their entirety on Sampo’s website at www.sampo.com/duallisting. Holders who wish to convert Nasdaq Helsinki listed Sampo A shares into SDRs, or vice versa, should liaise with their bank or broker to execute the conversion together with SEB.

During a period of 14 calendar days from and including the first day of trading in SDRs on Nasdaq Stockholm, the conversion fees charged by Euroclear Sweden and SEB as issuer of the SDRs for converting Sampo A shares to SDRs will be paid by Sampo. Any additional fees or costs charged by the shareholders’ own service providers will be borne by the shareholders.

Pursuant to a market maker and liquidity provider arrangement, SEB shall quote bid and ask prices continuously, for its own account, regarding the SDRs during normal trading hours of Nasdaq Stockholm. For each trading day, prices shall be quoted during at least 85 per cent of the continuous trading. Under normal trading conditions the maximum difference between the bid and ask prices (spread) shall be 2 per cent (or 4 per cent during Stressed Market Conditions, as defined in the Nasdaq Nordic Member Rules applicable from time to time) calculated from the bid price, and the aim is to keep a spread that is no more than 0.50 per cent wider than the spread of the Sampo A share traded on Nasdaq Helsinki. SEB shall during normal trading conditions quote bid and ask prices each in a minimum size of at least SEK 50,000.

Sampo will not raise new capital or make any offering as part of the dual listing on Nasdaq Stockholm. ABG Sundal Collier and Nordea are acting as financial advisors and Hannes Snellman as legal advisor to Sampo in conjunction with the dual listing.

Sampo disclosed on 8 September 2022 that it was evaluating a dual listing on Nasdaq Stockholm. On 2 November 2022, Sampo communicated that it was proceeding with the dual listing.

SAMPO PLC
Investor Relations and Group Communications

For further information, please contact:

Sami Taipalus
Head of Investor Relations
tel. +358 10 516 0030

Media enquiries:

Maria Silander
Communications Manager, Media Relations
tel. +358 10 516 0031

Distribution:
Nasdaq Helsinki
London Stock Exchange
The principal media
Financial Supervisory Authority
www.sampo.com

IMPORTANT INFORMATION

None of the information contained herein constitute an offer to sell, or the solicitation of an offer to buy or acquire, any shares, SDRs, rights or other securities of Sampo in any jurisdiction whatsoever, including but not limited to, Finland, Sweden, and other member states of the European Economic Area. The information contained herein has been furnished solely for the purpose of communicating about the listing and trading in Sampo A shares in the form of SDRs on Nasdaq Stockholm.

The information contained herein is not an offer for sale of securities in the United States. The shares, SDRs, rights or other securities of Sampo referred to have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration thereunder.

The information contained herein is not intended for, and must not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or Switzerland, and do not constitute an offer to sell or the solicitation of an offer to buy or acquire, any shares, SDRs, rights or other securities of the Sampo in the United States, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or Switzerland or any other country in which it would be contrary to the laws and regulations of that country.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 20228.12.2022 22:30:00 CET | Press release

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of sharesTotal number of voting rights11/30/2022 94,137,145 Total gross of voting rights: 94,137,145 Total net* of voting rights: 93,966,891 * Total net = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants8.12.2022 22:00:00 CET | Press release

Company announcement – No. 57 / 2022 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark and Boston, MA, U.S. December 8, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 64,919 divided into 64,919 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles o

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such8.12.2022 21:40:00 CET | Press release

COPENHAGEN, Denmark, December 8, 2022 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1.Details of the person discharging managerial responsibilities/person closely associateda)NamePaul Chaplin2.Reason for the notificationa)Position/status President and Chief Executive Officer of Bavarian Nordic A/S b)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameBavarian Nordic A/Sb)LEI2138006JCDVYIN6INP514.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the financial instrument, type of instrument Identification codeWarrants DK0015

Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer8.12.2022 21:40:00 CET | pressemeddelelse

KØBENHAVN, Danmark, 8. december 2022 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende medarbejdere og/eller personer/firmaer der er nærtstående til disse. 1.Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til dennea)NavnPaul Chaplin2.Årsag til indberetningena)Stilling/titelAdministrerende direktør i Bavarian Nordic A/Sb)Første indberetning/ændringFørste indberetning3.Nærmere oplysninger om udstederen, deltageren på markedet for emissionskvoter, auktionsplatformen, auktionsholderen eller den auktionstilsynsførendea)NavnBavarian Nordic A/Sb)LEI-kode2138006JCDVYIN6INP514.Nærmere oplysninger om transaktionen/transaktionerne: gentages for i) hver type instrument, ii) hver type transaktion, iii) hver dato og iv) hvert sted, hvor der er udført transaktionera)Beskrivelse af det finansielle instrument, instrumenttypen IdentifikationskodeTegningsoption

Bavarian Nordic iværksætter nyt incitamentsprogram for koncernledelsen og udvalgte medarbejdere8.12.2022 21:35:00 CET | pressemeddelelse

KØBENHAVN, Danmark, 8. december 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at bestyrelsen har besluttet at udstede tegningsoptioner til koncernledelsen og udvalgte medarbejdere i Bavarian Nordic koncernen. Som et nyt initiativ vil erhvervelsen (vesting) af tegningsoptioner for medlemmer af koncernledelsen være baseret på succesfuld opnåelse af relevante Key Performance Indicators (KPI’er). Beslutningen er truffet i henhold til generalforsamlingens bemyndigelser til bestyrelsen, jf. vedtægternes § 5b og 5c, og i overensstemmelse med selskabets vederlagspolitik. Der tildeles i alt 248.787 tegningsoptioner til medlemmer af koncernledelsen til en udnyttelseskurs på DKK 224,70 pr. aktie, svarende til markedskursen for Bavarian Nordics aktie på tildelingstidspunktet. Erhvervelse af tegningsoptionerne er betinget af forudgående opfyldelse af KPI’er, som fastsættes af bestyrelsen. Der tildeles i alt 683.264 tegningsoptioner til udvalgte medarbejdere i Bavarian Nordic koncernen til